08 April 2024
08 April 2024
The approval was based on data from the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 trials.
Despite a failed bid to expand Imfinzi’s treatment scope in NSCLC, the drug has proved effective in treating small cell lung cancer.
Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.
GSK’s Trelegy Ellipta has been approved as a maintenance therapy for both asthma and COPD in Singapore.
Recent campaigns have targeted children and young adults in low vaccine uptake areas amidst a rising number of measles cases.
The FDA granted the approval based on the findings from the Phase III KarMMa-3 trial.
AdAlta will hold a 75% stake in AdCella while SYNBV will own the remaining 25% before the next financing round.
Lonza will produce the drug at its facility in Portsmouth, US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
